In patients receiving allogeneic stem cell transplantation (SCT) for treatment of malignant hematologic disorders, residual leukemia can be assessed by different methodologic approaches including techniques based on PCR analysis of diseasespecific markers, such as gene rearrangements resulting from translocations, or clone-specific markers, such as immunoglobulin or T cell receptor rearrangements. These techniques are very sensitive, but their application is restricted to certain types of leukemia. By contrast, surveillance of residual patient hemopoiesis by PCR analysis of highly polymorphic microsatellite (STR) markers facilitates assessment of disease persistence or recurrence regardless of the underlying type of leukemia. In total leukocyte preparations derived from peripheral blood or bone marrow, the sensitivity of this technique mostly does not permit detection of minor, patient-derived cell fractions if they represent less than 1% of the entire leukocyte sample. 1, 2 However, the immunophenotype of the original leukemic clone can be used for fluorescence-activated cell sorter (FACS)-assisted separation of specific cell populations expected to harbor tumor cells, if present. It is feasible to isolate cell subsets constituting as little as 1% of the entire leukocyte population. 3 Specific enrichment of the cell fractions of interest prior to PCR analysis may therefore result in a twolog increase in the sensitivity of identifying potentially malignant cells of patient origin, permitting their detection within a 10 3 -10 4 -fold excess of donor-derived cells. We have investigated a series of 59 consecutive allogeneic stem cell transplantations in 50 pediatric patients with malignant hematologic disorders including acute lymphoblastic leukemia (ALL; n = 32), acute myeloid leukemia (AML; n = 13), chronic myelomonocytic leukemia (CMML; n = 7), and chronic myeloid leukemia (CML; n = 7). The cell subsets isolated by flow sorting which were subjected to analysis by STR-PCR included granulocytes, monocytes, NK cells, T cells (helper and suppressor subsets), B cells, stem cells, and populations targeted according to the original immunophenotype of the leukemic clone. 1 The cell populations were isolated by targeting appropriate combinations of the following surface markers: CD3
and CD56
+ . During an overall observation period of 4 years (median, 14 months), hematologic relapses were observed in nine instances (15.2%) including five patients with ALL (15.5% of the ALL cases), one with AML (7.7%), two with JMML (28.6%), and one with CML (14.3%). Relapses occurred between 7 weeks and 18 months post-transplant, with a median of 6 months ( Table 1) .
The kinetics of chimerism has been assessed by serial genotype analysis both within specific cell subsets and total leukocyte preparations. Serial investigation of specific leukocyte subsets derived from peripheral blood (PB) or bone marrow (BM) revealed informative changes in six of the nine patients who have experienced hematologic relapse. Of the remaining three patients, one (Table 1 ; No.3) was not available for chimerism analysis during more than a year prior to relapse. Investigation of a total leukocyte BM sample shortly before diagnosis of relapse revealed reappearance of mixed chimerism. In the other two patients, serial investigation by STR-PCR of flowsorted cell populations failed to show any changes suggestive of impending relapse. One of these patients (Table 1 ; No. 4) displayed complete chimerism in all cell subsets derived from PB or BM samples analyzed at five time-points during the first 4 months post-transplant, until extramedullary relapse (liver, CNS) has been diagnosed. In the other patient (Table 1; No. 6), investigation of flow-sorted cells from PB and/or BM was performed at five time-points during a period of 5 months post-SCT, and revealed CC in all relevant cell subsets investigated. Six months post-transplant, the patient developed thrombocytopenia which prompted a BM investigation. At this time, the leukemic blasts were already visible upon morphological analysis.
Among the six patients with informative changes in chimerism prior to relapse, five showed persistence or reappearance of autologous allelic patterns within cell populations indicative of leukemic cells (Table 1 ; Nos 2, 5, 7, 8, and 9). In one patient (Table 1 ; No. 1), the only observation made before hematologic relapse was lineage-specific chimerism kinetics suggestive of graft rejection.
In two patients with ALL ( 
/CD19
+ cell fractions after a period of CC within all cell populations derived both from PB and BM.
In a patient with CMML (Table 1 ; No. 7), a persisting CD34
+ cell subset of recipient origin (PG) was detected in PB samples at all time-points until hematologic relapse has occurred 7 months post-transplant. Moreover, mixed chimerism in the NK and CD19
+ populations has reappeared 6 months before relapse.
Another patient with CMML (Table 1 ; No. 8) displayed pure or nearly pure CC in all cell subsets tested during 12 sub- sequent STR-PCR analyses of flow-sorted populations from PB (nine time-points) or BM (three time-points) within a period of 6 months post-transplant. The first change observed was reappearance of MC in the CD19 + fraction in a PB sample 3 months prior to relapse (Figure 1a) . The following analyses within this cell subset over the next 7 weeks showed increase of recipient chimerism until virtually pure PG was observed. At this time, PB and BM analyses revealed reappearance of MC also in other cell subsets (Figure 1b) . Hematologic relapse has been detected 5 weeks later by morphological investigation of the BM. The results of chimerism analysis at this time-point are shown in Figure 1c .
In a patient with CML (Table 1 ; No. 9), early establishment of CC was observed in flow-sorted populations from PB (three time-points) and BM (one time-point). Six weeks posttransplant, the CD19 + cell subset showed a switch from CC to PG. A BM investigation performed shortly thereafter indicated incipient lymphoid blast crisis upon morphological investigation.
Another recurrent finding in patients who experienced a relapse was persistence or reappearance of autologous T cells (CD3 + ) and/or the CD4 + (helper) and CD8 + (suppressor) subsets. This observation was made in three of the patients presented (Table 1 ; Nos 1, 7, and 9).
A child with ALL ( + cells showed increasing patient-specific allelic signals. The observations within the T cell compartment were the only changes detected by chimerism analysis prior to relapse. Blast cells of recipient origin were first identified by STR-PCR in the BM 7 weeks posttransplant, at which time they were also amenable to detection by morphological investigation (Figure 2 ).
In one of the patients with CMML studied ( 
Figure 2
Kinetics of lineage-specific chimerism after T celldepleted allogeneic peripheral SCT in a child with ALL (Table 1 Leukemia transplant, after a period of complete chimerism. Two weeks later, morphological examination of the BM revealed incipient lymphoid blast crisis which had been heralded by reappearance of patient-derived CD19 + cells in PB (see above). In the majority of relapsed patients, serial investigation of chimerism within specific leukocyte subsets revealed findings suggestive of impending disease recurrence or rejection of the graft. Conversely, chimerism testing did not show similar findings in any of the patients who experienced neither graft rejection nor relapse. It should be emphasized that in most instances the dynamics of chimerism observed in cell subsets isolated by flow sorting has escaped detection in analyses of DNA derived from total leukocyte preparations, because of the small size of the cell populations involved. This observation is in contrast to a recent study indicating that increasing recipient chimerism in WBC fractions from PB provides an early indication of imminent relapse in most instances.
2 Earlier studies using highly sensitive PCR approaches for the assessment of chimerism, such as amplification of Y-chromosomederived sequences in sex-mismatched SCT, indicated that the detection of MC lower than 1% has no predictive value regarding relapse. 4, 5 Our observations are not in line with this notion. Investigation of chimerism within flow-sorted cell subsets permits detection of autologous cells at a sensitivity of 0.1-0.01%. The experience gained from our studies suggests that identification of persisting recipient cells at this level of sensitivity and assessment of the kinetics of chimerism within particular subsets may provide information on imminent relapse at a time at which no changes are detected by PCR genotype analysis of total leukocyte samples. In our series, the kinetics of chimerism within specific cell subsets often provided the first indication of impending disease recurrence, and prompted subsequent investigational efforts which ultimately permitted the diagnosis of hematologic relapse. The time span between the observation of changes in chimerism described above and the diagnosis of hematologic relapse was up to 3-6 months. As indicated, investigation of immunologic subsets expected to harbor leukemic cells, if present, is approximately two logs more sensitive than analysis of total leukocytes. This sensitivity is in the range of other approaches to detection of minimal residual disease (MRD) including the analysis of leukemia-associated immunophenotypes by flow cytometry and PCR analysis of immunoglobulin/T cell receptor rearrangements or translocation-associated fusion gene transcripts. Investigation of chimerism, however, does not only permit indirect assessment of residual disease. It also provides insight into immunologic processes indicative of graft rejection which may be a condition facilitating subsequent relapse. In our series, graft rejection has been detected by monitoring of chimerism in three patients with leukemia who had received T celldepleted peripheral blood stem cell (PBCS) transplants.
1 All patients were retransplanted within a short period of time which might have prevented recurrence of the disease. Similar observations within the T cell compartment, ie persistence of autologous cells or increasing recipient chimerism, were made in three patients who have experienced hematologic relapse (Table 1 ; Nos 1, 7 and 9). Two of the patients (Nos 1 and 9) had also received T cell-depleted PBCS grafts. Since T cells can survive intensive conditioning regimens, monitoring of chimerism during the post-transplant period often reveals recipient allelic signals within this cell subset. Earlier studies have demonstrated that prolonged MC within CD3 + (CD4 + /CD8 + ) cells after allogeneic SCT is not associated with a significantly increased risk of leukemia relapse. 6 However, the kinetics of chimerism in the T cell compartment, ie the reappearance PG after CC or the detection of increasing recipient signals, appears to be a clinically useful parameter for early assessment of graft rejection. In view of the fact that immunologic host reactions against the allograft may be followed by rapid onset of relapse, serial investigation of genotype within specific cell compartments may provide a basis for timely therapeutic considerations. 7 Taken together, the data available indicate that monitoring of chimerism in patients after allogeneic SCT, particularly the investigation of specific cell populations, extends the diagnostic possibilities for timely detection of impending relapse. 8 
